Trends in the Management of Nonviable Pregnancies of Unknown Location in the United States

Gynecol Obstet Invest. 2018;83(6):552-557. doi: 10.1159/000488760. Epub 2018 Jun 6.

Abstract

Background: When managing a nonviable pregnancy of unknown location (PUL), a debate has emerged in the literature whether to perform uterine curettage for definitive diagnosis of pregnancy location or administer methotrexate for a presumed ectopic pregnancy. The purpose of this study is to describe the treatment patterns when managing a PUL.

Methods: A prospective, anonymous Internet based-electronic survey of PUL case scenarios was administered to a random sample of physicians across the United States.

Results: A total of 214 physicians responded. When presented with a PUL by ultrasound and a βhCG measurement of 3,270 mIU/mL, which is above the discriminatory level, 88.3% (188) would choose an additional βhCG measurement before recommending any intervention. When presented with a PUL by ultrasound and serial βhCG measurements demonstrating an inappropriate trend for a viable gestation, 36.5% would offer uterine curettage and 31.3% would offer methotrexate. Resident and private clinicians had a fourfold lower adjusted odds of choosing uterine curettage compared to academic physicians.

Conclusions: Based on our findings, there does not appear to be a consensus regarding the management of a PUL.

Keywords: Abnormal intrauterine pregnancy; Ectopic pregnancy; Methotrexate; Pregnancy of unknown location; Uterine curettage.

MeSH terms

  • Abortifacient Agents, Nonsteroidal / administration & dosage*
  • Chorionic Gonadotropin, beta Subunit, Human / blood
  • Dilatation and Curettage / statistics & numerical data*
  • Female
  • Health Surveys
  • Humans
  • Male
  • Methotrexate / administration & dosage*
  • Practice Patterns, Physicians' / trends*
  • Pregnancy
  • Pregnancy, Ectopic / therapy*
  • Prospective Studies
  • Ultrasonography / statistics & numerical data
  • United States

Substances

  • Abortifacient Agents, Nonsteroidal
  • Chorionic Gonadotropin, beta Subunit, Human
  • Methotrexate